• Je něco špatně v tomto záznamu ?

Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study

F. Lohrmann, A. Efstratiou, UBS. Sørensen, R. Creti, A. Decheva, P. Křížová, J. Kozáková, J. Rodriguez-Granger, M. De La Rosa Fraile, I. Margarit, D. Rinaudo, D. Maione, J. Telford, G. Orefici, M. Kilian, B. Afshar, P. Melin, R. Berner, M....

. 2025 ; 53 (1) : 373-381. [pub] 20240908

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010135

Grantová podpora
200481 Seventh Framework Programme

INTRODUCTION: Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD). METHODS: Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study. Clinical obstetrical information was collected by a standardized questionnaire. GBS strains were characterized by serological and molecular methods. RESULTS: Among GBS carriers included in this study after testing positive for GBS by vaginal or recto-vaginal sampling, 13.4% had at least one additional obstetrical risk factor for EOD. The five most common capsular types (i.e., Ia, Ib, II, III and V) comprised ~ 93% of GBS carried. Of the colonized women, 77.8% received any IAP, and in 49.5% the IAP was considered appropriate. In our cohort, nine neonates presented with GBS early-onset disease (EOD) with significant regional heterogeneity. CONCLUSIONS: Screening methods and IAP rates need to be harmonized across Europe in order to reduce the rates of EOD. The epidemiological data from eight different European countries provides important information for the development of a successful GBS vaccine.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010135
003      
CZ-PrNML
005      
20250429134633.0
007      
ta
008      
250415s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s15010-024-02380-0 $2 doi
035    __
$a (PubMed)39244714
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Lohrmann, Florens $u Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany
245    10
$a Maternal Streptococcus agalactiae colonization in Europe: data from the multi-center DEVANI study / $c F. Lohrmann, A. Efstratiou, UBS. Sørensen, R. Creti, A. Decheva, P. Křížová, J. Kozáková, J. Rodriguez-Granger, M. De La Rosa Fraile, I. Margarit, D. Rinaudo, D. Maione, J. Telford, G. Orefici, M. Kilian, B. Afshar, P. Melin, R. Berner, M. Hufnagel, M. Kunze, DEVANI Study Group
520    9_
$a INTRODUCTION: Despite national guidelines and use of intrapartum antibiotic prophylaxis (IAP), Streptococcus agalactiae (group B streptococci (GBS)) is still a leading cause of morbidity and mortality in newborns in Europe and the United States. The European DEVANI (Design of a Vaccine Against Neonatal Infections) program assessed the neonatal GBS infection burden in Europe, the clinical characteristics of colonized women and microbiological data of GBS strains in colonized women and their infants with early-onset disease (EOD). METHODS: Overall, 1083 pregnant women with a GBS-positive culture result from eight European countries were included in the study. Clinical obstetrical information was collected by a standardized questionnaire. GBS strains were characterized by serological and molecular methods. RESULTS: Among GBS carriers included in this study after testing positive for GBS by vaginal or recto-vaginal sampling, 13.4% had at least one additional obstetrical risk factor for EOD. The five most common capsular types (i.e., Ia, Ib, II, III and V) comprised ~ 93% of GBS carried. Of the colonized women, 77.8% received any IAP, and in 49.5% the IAP was considered appropriate. In our cohort, nine neonates presented with GBS early-onset disease (EOD) with significant regional heterogeneity. CONCLUSIONS: Screening methods and IAP rates need to be harmonized across Europe in order to reduce the rates of EOD. The epidemiological data from eight different European countries provides important information for the development of a successful GBS vaccine.
650    _2
$a lidé $7 D006801
650    12
$a Streptococcus agalactiae $x izolace a purifikace $x klasifikace $7 D013292
650    12
$a streptokokové infekce $x epidemiologie $x mikrobiologie $x prevence a kontrola $7 D013290
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a těhotenství $7 D011247
650    _2
$a novorozenec $7 D007231
650    _2
$a dospělí $7 D000328
650    12
$a infekční komplikace v těhotenství $x epidemiologie $x mikrobiologie $7 D011251
650    _2
$a přenašečství $x epidemiologie $x mikrobiologie $7 D002353
650    _2
$a vagina $x mikrobiologie $7 D014621
650    _2
$a mladý dospělý $7 D055815
650    _2
$a vertikální přenos infekce $x statistika a číselné údaje $x prevence a kontrola $7 D018445
650    _2
$a antibiotická profylaxe $7 D019072
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Efstratiou, Androulla $u UK Health Security Agency, London, UK
700    1_
$a Sørensen, Uffe B Skov $u Department of Biomedicine, Health, Aarhus University, Aarhus, Denmark
700    1_
$a Creti, Roberta $u Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy
700    1_
$a Decheva, Antoaneta $u National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
700    1_
$a Křížová, Pavla $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Kozáková, Jana $u National Institute of Public Health, Prague, Czech Republic
700    1_
$a Rodriguez-Granger, Javier $u Servicio Andaluz de Salud, Hospital Universitario Virgen de Las Nieves, Granada, Spain
700    1_
$a De La Rosa Fraile, Manuel $u Servicio Andaluz de Salud, Hospital Universitario Virgen de Las Nieves, Granada, Spain
700    1_
$a Margarit, Immaculada $u GSK Vaccines, Siena, Italy
700    1_
$a Rinaudo, Daniela $u GSK Vaccines, Siena, Italy
700    1_
$a Maione, Domenico $u GSK Vaccines, Siena, Italy
700    1_
$a Telford, John $u GSK Vaccines, Siena, Italy
700    1_
$a Orefici, Graziella $u Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy
700    1_
$a Kilian, Mogens $u Department of Biomedicine, Health, Aarhus University, Aarhus, Denmark
700    1_
$a Afshar, Baharak $u UK Health Security Agency, London, UK
700    1_
$a Melin, Pierrette $u Department of Clinical Microbiology, National Reference Center Streptococcus Agalactiae, University Hospital Center of Liege, Liege, Belgium
700    1_
$a Berner, Reinhard $u Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
700    1_
$a Hufnagel, Markus $u Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany
700    1_
$a Kunze, Mirjam $u Department of Obstetrics and Gynecology, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany. mirjam.kunze@uniklinik-freiburg.de
710    2_
$a DEVANI Study Group
773    0_
$w MED00002234 $t Infection $x 1439-0973 $g Roč. 53, č. 1 (2025), s. 373-381
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39244714 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134628 $b ABA008
999    __
$a ok $b bmc $g 2311485 $s 1247216
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 53 $c 1 $d 373-381 $e 20240908 $i 1439-0973 $m Infection $n Infection $x MED00002234
GRA    __
$a 200481 $p Seventh Framework Programme
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace